InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,724.80
(
0.01%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
82.91
(
-0.37%
)
Bitcoin
61,787.09
(
-1.78%
)
Post# of 97237
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

zino

Send PM Follow Ignore
Followers 336
Posts 19020
Boards Moderated 0
Alias Born 08/25/2007

zino

Re: None

Saturday, 11/11/2017 3:21:17 PM

Saturday, November 11, 2017 3:21:17 PM

Post# of 97237
ARGS..Phase3 Trial News

The average number of antigen-specific memory T-cells after the seventh dose was approximately double the number observed before treatment. This increase was found to be statistically significant
http://crweworld.com/article/news-provided-by-globenewswire/175537/argos-therapeutics-provides-update-on-immunology-data-from-the-phase-3-adapt-trial-presented-at-the-sitc-2017-annual-meeting

DONT LISTEN TO ME IM CANADIANNNNNNNN

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up